Southern Acids (M) Berhad, an investment holding company, (5134) Fair Value & Analysis
Industrials · MY · Market cap 430M MYR
Fair value as of: Jun 26, 2026
Analysis
Southern Acids (M) Berhad, an investment holding company, (5134) currently trades at 3.14 MYR, while our model-based Fair Value estimate is 4.56 MYR — implying the stock looks roughly 45.2% undervalued today. We read business quality at 97/100 (high quality), in the Industrials sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high) — always confirm before acting.
About the company
Southern Acids (M) Berhad, an investment holding company, engages in the manufacture and trading of oleochemical products in Malaysia, Indonesia, Asia, Europe, the United States, and internationally. The company operates through four segments: Oleochemical Manufacturing, Milling & Cultivation, Investments & Services, and Healthcare Services. It offers fatty acids and glycerine for use in various applications, including personal care, cleaning agents, cosmetic, pharmaceutical, and food products. It is also involved in the processing of fresh fruit bunches into crude palm oil and palm kernel, as well as oil palm cultivation activities. In addition, it operates private hospital in Klang for the provision of cardiology, hand and microsurgery, nephrology, neurosurgery, orthopaedic surgery, obstetrics and gynaecology, radiotherapy, oncology services, cancer, fertility, cardiac care, and E.N.T. head and neck surgery. Further, it provides plantation; administrative; overhead conveyor goods …
Open the full interactive analysis →
Similar stocks
Frequently asked questions
Is Southern Acids (M) Berhad, an investment holding company, (5134) undervalued?
What is the fair value of 5134?
What is the quality score of 5134?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.